The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,958.00
Bid: 1,951.00
Ask: 1,953.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.103%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,958.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Thursday broker round-up UPDATE

Thu, 17th Jul 2014 11:07

Antofagasta: Canaccord Genuity cuts target price from 870p to 835p and maintains a hold recommendation.African Minerals: Canaccord Genuity reduces target price from 230p to 170p and keeps a buy recommendation.Ashmore Group: Goldman Sachs downgrades to neutral with a target price of 430p.Barclays: Exane reduces target price from 280p to 225p retaining a neutral rating.BHP Billiton: Goldman Sachs lowers target price from 1820p to 1810p retaining its neutral rating. Canaccord Genuity reduces target price from 2100p to 1935p and keeps a hold recommendation.Big Yellow Group: Morgan Stanley raises target price from 445p to 615p and upgrades from equal-weight to overweight.Central Asia Mining: Canaccord Genuity lowers target price from 200p to 190p retaining its buy recommendation.City of London Investment Group: N+1 Singer raises target price from 220p to 317p and upgrades to buy.Croda International: Barclays reduces target price from 2330p to 2100p and downgrades from equal-weight to underweight.Diageo: JP Morgan cuts target price from 1780p to 1760p and downgrades from neutral to underweight.Drax Group: Citi cuts target price from 750p to 700p downgrading from buy to neutral.EMIS: Panmure Gordon moves target price from 851p to 858p keeping a buy recommendation. N+1 Singer moves target price from 820p to 830p and retains a buy recommendation.International Ferro Metal: Numis places both its target price and its buy recommendation under review.Fesnillo: Deutsche Bank takes target price from 870p to 890p and maintains a hold recommendation. JP Morgan ups target price from 1030p to 1100p and retains an overweight rating.Friends Life Group: Berenberg ups target price from 310p to 330p and keeps a hold recommendation.Gable Holdings: Panmure Gordon moves target from 92p to 105p and retains a buy recommendation.Genel Energy: Canaccord Genuity reduces target price from 1230p to 1100p, while its buy recommendation remains kept.Glencore Xstrata: Goldman Sachs shifts target price from 295p to 300p and stays with its neutral rating.Greene King: JP Morgan reduces target price from 940p to 890p leaving its neutral rating unaltered.Gulf Keystone: Canaccord Genuity shifts target price from 95p to 100p and keeps a hold recommendation.Hikma Pharmaceuticals: UBS raises target price from 1700p to 2000p and upgrades from neutral to buy.Hilton Food Group: Numis cuts target price from 610p to 592p and retains an add rating.ICAP: UBS lowers target price from 330p to 320p and keeps a sell recommendation. Citi cuts target price from 385p to 370p and leaves its neutral rating unchanged.ITV: Investec places both its target price (prev.: 195p) and its hold recommendation under review.Judges Scientific: WH Ireland reduces target price from 2370p to 1550p and stays with its neutral rating.Kazakhmys: Canaccord Genuity shifts target price from 260p to 265p, while downgrading from hold to sell.Lancashire: JP Morgan cuts target price from 744p to 725p and stays with its neutral rating.Oxford Instruments: N+1 Singer reduces target price from 1445p to 1350p and maintains a hold recommendation.Phoenix Group Holdings: Berenberg upgrades from hold to buy with a target price of 750p.Rexam: Deutsche Bank ups target price from 550p to 570p, while downgrading from buy to hold.Ricardo: Oriel places both its target price (prev.: 670p) and its reduce rating under review.Rio Tinto: Goldman Sachs lowers target price from 2530p to 2520p reiterating its strong sell recommendation. JP Morgan ups target price from 4100p to 4150p and stays with its overweight rating. Canaccord Genuity cuts target price from 4200p to 4145p and reiterates a buy recommendation.Royal Mail: Deutsche Bank reduces target price from 587p to 486p and retains a hold recommendation. JP Morgan cuts target price from 765p to 745p and stays with an overweight rating.Thomas Cook Group: Numis reduces target price from 175p to 135p and maintains its hold recommendation.Trinity Exploration & Production: Investec places its target price (prev.: 250p) under review, while keeping a buy recommendation.Tullow Oil: Canaccord Genuity reduces target price from 950p to 850p and stays with its hold recommendation.Weatherly International: Canaccord Genuity lowers target price from 6p to 5p and keeps its buy recommendation.
More News
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Oct 2021 09:51

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

Read more
27 Sep 2021 12:14

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.